Abstract: Hybridoma cell lines and transformed B-cell lines are derived from B-cells of cancer patients actively immunized with autologous tumor antigens and used to produce monoclonal antibodies having specificity for tumor-associated antigens. The monoclonal antibodies can be used in both diagnostic procedures and therapy for human cancers.

Abstract: Disclosed is a two compartment syringe having at least two by-passes which selectively allow an easy flow from one compartment to the other compartment.The liquid (injection fluid) is in the "needle" compartment and the solid medicament is in the "plunger" compartment. Associated with the plunger compartment is an aperture or other means for allowing the escape of fluids from that compartment during a lyophilization process.

Abstract: A bacteriophage directional cloning vector containing a multiple cloning site, a method for preparing cDNAs that can be cloned in a unique orientation and a bifunctional oligodeoxynucleotide linker, which creates a unique restriction site when ligated to the 3' end of cDNA fragments. The simple and efficient cDNA cloning system reduces the amount of RNA and effort required for the preparation of large directionally cloned libraries by providing a unique vector that accepts cDNA fragments in a unique 5'-3' orientation and by providing a unique bifunctional linker that facilitates the preparation of cDNA fragments that can be ligated directionally into the vector.

Abstract: The invention relates to tetrahydronaphthalene and indane derivatives with the general formula I: ##STR1## wherein R.sup.1 represents zero to four substituents, which may be the same or different and are selected from OH, halogen, NO.sub.2, CN, CF.sub.3, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy and unsubstituted or C.sub.1 -C.sub.4 alkyl substituted amino;R.sup.2 represents C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkenyl and C.sub.1 -C.sub.4 alkynyl which may be substituted by halogen;R.sup.3 and R.sup.4 represent independently H, C.sub.1 -C.sub.4 alkyl or form together with the nitrogen atom a 5- or 6-membered ring;n has the value 0 or 1;ALK is an aliphatic hydrocarbon with 1-8 carbon atoms and their pharmaceutically acceptable salts.These new compounds are typical monoamine reuptake blockers with additional .alpha..sub.2 antagonist activity and show strong anti-depressant activity without being sedative.

Abstract: The invention relates to novel tetracyclic compounds with an anti-depressant action, without neuroleptic or sedative side effects, of the general formula I ##STR1## and also functional derivatives hereof, wherein: R.sup.1 represents one or two identical or different substituents denoting H, OH, halogen, C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkoxy;R.sup.2 represents one or two identical or different substituents having the same meaning as R.sup.1 ;R.sup.3 and R.sup.4 are two substituents which are in the cis configuration and of which one is H and the other is OH;R.sup.5 is H or C.sub.1 -C.sub.4 alkyl;X denotes O or S;n is 0 or 1.

Abstract: Thermochemically induced luminescence is generated in a fluorescent labeled organic compound containing a covalently bonded fluorescent label which is a polycyclic aromatic radical having at least three linearly fused benzene rings and capable of being excited to a fluorescent electronic excited state by energy transfer from an energy donor molecule or radical having an electronic excited state, by a process comprising generating an energy donor radical or molecule by a thermochemical reaction in the presence of the fluorescent label. The energy donor radical may be generated by a chemical reaction in the presence of the fluorescent labeled organic compound or the fluorescent labeled compound itself may be additionally labeled with a radical capable of being excited to an electronic excited state by a thermochemical reaction, i.e., by a process initiated by adsorption of thermal energy.

Abstract: Pharmaceutical composition which is useful as a medicinal product, in particular for the treatment of disorders of the central nervous system, characterized in that it contains customary pharmaceutical excipients, and at least one of the compounds of formula ##STR1## in which the trifluoromethyl substituent is at the 4-position, at the 5-position, or at 4- and 5-positions of the pyridinyl ring, and the substituent R denotes either hydrogen or a halogen, such as chlorine, at position(s) of the pyridinyl ring not occupied by CF.sub.3, and its pharmaceutically acceptable salts.

Abstract: The invention relates to an implant of polymeric material which can release a contraceptive agent for a relatively long time when fitted subcutaneously or locally. The implant comprises a core material of ethylene/vinyl acetate copolymer which functions as a matrix for a contraceptive substance, an ethylene/vinyl acetate membrane encasing the core material, and a contact layer at the interface of the core material and membrane which prevents the separation of the core material from the membrane. The implant of the invention is made by a co-extrusion process.

Abstract: The invention relates to pyridazinone compounds of the general formula I: ##STR1## wherein R.sup.1 represents one to four substituents, which may be the same or different and are selected from H, OH, halogen, NO.sub.2, unsubstituted or C1-C4 alkyl substituted amino, C1-C4 alkyl, C1-C4 halogen substituted alkyl, O--ALK--NR.sup.4 R.sup.5, C1-C4 alkoxy, whereby two substituents taken together may also represent a methylenedioxy group;R.sup.2 and R.sup.3 represent independently H or C1-C4 alkyl;R.sup.4 and R.sup.5 represent independently H or C1-C4 alkyl, or form together with the nitrogen a 5- or 6- membered ring;X represents S or O;the dotted line represents an optional bond;and their pharmaceutically acceptable salts.

Abstract: Antigens characteristic of all species of Listeria except L. denitrificans comprising proteins found in Listeria heat extracts, the major antigen having a molecular weight of from about 30 to about 38KD and comprising three immunogenically different epitopes and others comprising proteins having a molecular weight range of approximately 17KD to the major antigen and comprising an epitope immunoreactive with antibodies that are also reactive with one of the three epitopes on the 30 to about 38KD protein. The invention also comprises mouse monoclonal antibodies specifically reactive with the identified epitopes on these antigens.

Abstract: Monoclonal antibodies specific for Mycoplasma pneumoniae determinants and their use in the diagnosis of mycoplasma pneumoniae and purification of a protein determinant of M. pneumoniae.

Abstract: An instrument and a sealable, sterilizable vessel for detecting the presence of microorganisms in a specimen, the vessel containing a liquid culture medium and a sensor means with an indicator medium therein. Changes in the indicator medium resulting from pH change or change in CO.sub.2 concentration in the medium are detected from outside the vessel.

Abstract: A substituted 1-(2-chloroethyl)-3-acyl-3-alkyltriazene of the formula: ##STR1## in which R.sub.1 is 1-oxoalkyl containing from two to eight carbon atoms, fluorinated 1-oxoalkyls containing from two to eight carbon atoms and substituted with up to three fluorine atoms, benzoyl, phenylacetyl, carboalkoxy containing from two to eight carbon atoms, fluorinated carboalkyl containing from two to eight carbon atoms and up to three fluorine atoms, carbophenoxy, N-phenyl aminocarbonyl, N-alkyl aminocarbonyl containing from two to eight carbon atoms, thiocarbamoyl, N-alkylthiocarbamoyls with from two to eight carbon atoms, N-phenylthiocarbamoyl, dialkylphosphonates in which the alkyl groups can be the same or different and each contains from one to seven carbon atoms, phenylsulfonyl, and meta or para-substituted phenylsulfonyl in which the meta or para substituent is methyl, ethyl, methoxy, ethoxy, fluoro and chloro; and R.sub.

Abstract: The invention relates to new 11-arylsteroid compounds, having a strong antiprogestin and a weak or nonexistent antiglucocorticoid activity, to processes for preparing said compounds and also to pharmaceutical preparations which contain these derivatives as active constituent, characterized in that said steroids have the following formula: ##STR1## in which R.sub.1 is an aryl group with a ##STR2## group as substituent, X and Y each being separately H or a (1-4 C) hydrocarbyl group or together a (2-C) hydrocarbyl group which forms a 3- to 7-membered ring together with the nitrogen atom;R.sub.2 is hydrogen, hydroxyl, an acyloxy or an alkoxy group or a saturated or unsaturated hydrocarbyl group containing 1-8 carbon atoms, which hydrocarbyl group is provided with at least one hydroxyl, oxo, azido, cyano and/or halogen group;R.sub.3 is a hydroxyl, an acyloxy or an alkoxy group or an acyl group optionally substituted by a hydroxyl, alkoxy, acyloxy or halogen group; or R.sub.2 and R.sub.

Abstract: The invention relates to an injection device, in particular for once-only use, for injecting an implant which can release a drug in a controlled manner, which device comprises a housing which is provided at the injection end with an injection needle in which the implant can be disposed and in which a passage opening is disposed at the actuating end of the housing for a plunger, mounted in the housing and displaceable in the axial direction of the needle, which, on the one hand, can interact with the implant and, on the other hand, is provided with an actuating element, which element is constructed as an element for pressing and supporting against or on the part of the body to be treated.

Abstract: The invention relates to a pharmaceutical dosage unit for oral application for preventing or treating climacteric complaints.

Abstract: The present invention deals with dibenzo-oxocin-, dibenzo-thiocin-, dibenzo-azocin- and dibenzocyclo-octenamine derivatives suitable for use as antipsychotic compounds without extra-pyrimidal side-effects.

Abstract: The present invention relates to new amino-thiazole and amino-oxazole derivatives of the general formula: ##STR1## wherein: R represents hydrogen, a lower alkyl group with 1 to 4 carbon atoms, a lower alkenyl group, a phenyl-alkyl (1-4 C), furanyl-alkyl (1-4 C) or thienyl-alkyl (1.varies.4 C) group;X represents sulphur or oxygen;R.sub.1 and R.sub.2 represent hydrogen or alkyl (1-4 C), andthe dotted line represents an optional extra bond,as well as pharmaceutically acceptable acid addition salts thereof, having potent dopamine-agonist activity.

Abstract: According to the present invention antibody preparations are more stable during storage if in addition they contain a mixture of at least one polyoxypropylene-polyoxyethylene block polymer (such as Pluronic F68) and at least one phospholipid (such as lecithin).

Abstract: An aqueous stabilized enzyme preparation to be used for measuring the amount of .alpha.-amylase in a liquid sample like serum or urine containing a blocked and labeled oligosaccharide being the substrate for the .alpha.-amylase to be measured in the presence of exo-enzymes which aqueous preparation, preferably consisting of two separate solutions is stabilized by adding a buffer, a taurocholic acid derivative, an albumin, and a polyhydric alcohol.